June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Papilledema Outcome Evaluation in the OCT Substudy of theIdiopathic Intracranial Hypertension Treatment Trial
Author Affiliations & Notes
  • Mark J Kupersmith
    Neuro-Ophthalmology, Roosevelt Hospital and NYEE, New York, NY
    Icahn School of Medicine at Mount Sinai, New York City, NY
  • Footnotes
    Commercial Relationships Mark Kupersmith, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2235. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mark J Kupersmith, OCT Sub-Study Committee for the NORDIC Idiopathic Intracranial Hypertension Study Group; Papilledema Outcome Evaluation in the OCT Substudy of theIdiopathic Intracranial Hypertension Treatment Trial. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2235.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To demonstrate the effect of therapy on quantitative imaging of papilledema in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). The IIHTT showed that acetazolamide (ACZ) was efficacious in improving mild visual field loss in patients with IIH. We showed that spectral domain optical coherence tomography (SD-OCT) combined with custom 3-segmentation analysis provides reliable continuous measurements of structural changes in the optic nerve head and retina due to papilledema (OCT Sub-Study Committee, IOVS in press).

Methods: Eighty-nine (43 ACZ, 46 placebo treated) IIHTT subjects were evaluated at study entry and at 3 and 6 months with standard automated perimetry, Frisén grading of photos, high and low contrast visual acuity, and OCT imaging using the Cirrus SD-OCT. OCT data were analyzed using custom 3-D segmentation algorithms to calculate retinal nerve fiber layer (RNFL), total retinal thickness (TRT), optic nerve volume (ONHV), and retinal ganglion cell layer (GCL) measurements. Results for ‘study eyes’ (with worse perimetric mean deviation, PMD, at baseline) were used for most analyses.

Results: At study entry, distributions of OCT measures were similar in both treatment groups. At 6 months, ACZ group eyes showed greater mean reductions in RNFL (175 µm vs. 89 µm, p=0.001), TRT (220 µm vs. 113 µm, p=0.001), and ONHV (4.9 mm3 vs. 2.1 mm3, p=0.001) than placebo group eyes. For both treatment groups, subjects with weight loss > 6% had greater mean reductions in RNFL (156 µm vs. 103 µm, p=0.01), TRT (201 µm vs 127 µm, p=0.003), and ONHV (4.3 mm3 vs. 2.6 mm3, p=0.002) than those with less weight loss. GCL thinning was minor in the ACZ (3.6 µm) and placebo (2.1 µm) groups. Interocular correlations were > 0.8 for all 3-D segmentation derived measurements. At 6 months, RNFL, TRT, and ONHV correlated with Frisén grade (r=0.48-0.59, p<0.0001). At 6 months, the 21 eyes with GCL thickness <5th percentile of controls had worse PMD (p=0.01) and both high (p=0.05) and low (p=0.01) contrast acuity than for eyes with GCL > 5th percentile.

Conclusions: OCT measures of swelling due to papilledema in IIH are effectively improved with ACZ and weight loss. In contrast to the strong correlation at baseline (IOVS in press), 6 month RNFL, TRT, and ONHV show only moderate correlations with papilledema grade.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.